A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans
about
Turning-Off Signaling by Siglecs, Selectins, and Galectins: Chemical Inhibition of Glycan-Dependent Interactions in CancerGalectins and their ligands: negative regulators of anti-tumor immunityGalectin-3 in angiogenesis and metastasis.Carbohydrate sequence of the prostate cancer-associated antigen F77 assigned by a mucin O-glycome designer array.Differential expression patterns of N-acetylglucosaminyl transferases and polylactosamines in uterine lesions.Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attackDetection of Core2 β-1,6-N-Acetylglucosaminyltransferase in Post-Digital Rectal Examination Urine Is a Reliable Indicator for Extracapsular Extension of Prostate CancerTumor-Associated Glycans and Immune SurveillanceTwo opposing roles of O-glycans in tumor metastasis.Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration.Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma.I-branching N-acetylglucosaminyltransferase regulates prostate cancer invasiveness by enhancing α5β1 integrin signalingImmunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer.Downregulation of miR-302c and miR-520c by 1,25(OH)2D3 treatment enhances the susceptibility of tumour cells to natural killer cell-mediated cytotoxicityPerspectives on Anti-Glycan Antibodies Gleaned from Development of a Community Resource DatabaseThe critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity.Glycobiology of immune responsesAltered tumor-cell glycosylation promotes metastasis.Sticking to sugars at the metastatic site: sialyltransferase ST6GalNAc2 acts as a breast cancer metastasis suppressor.Recent progress and perspectives on prostate cancer biomarkers.Targeting NKG2D in tumor surveillance.Mucins in pancreatic cancer and its microenvironment.Evolving mechanistic insights into galectin functions.Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.Branched I antigens on leukemia cells enhanced sensitivity against natural killer-cell cytotoxicity through affecting the target-effector interaction.Core2 O-glycan-expressing prostate cancer cells are resistant to NK cell immunity.MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasisNK Cell Exhaustion.Association between circulating galectin-3 levels and the immunological, inflammatory and nutritional parameters in patients with colorectal cancerStage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer.The role of LIM and SH3 protein-1 in bladder cancer metastasis.Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z.Molecular Pathways: Mucins and Drug Delivery in Cancer.Alterations of the Human Skin N- and O-Glycome in Basal Cell Carcinoma and Squamous Cell Carcinoma.A Developed NK-92MI Cell Line with Siglec-7neg Phenotype Exhibits High and Sustainable Cytotoxicity against Leukemia Cells.Molecular basis for intestinal mucin recognition by galectin-3 and C-type lectins.Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma.The Role of Galectins in Cervical Cancer Biology and Progression.Microenvironmental niche divergence shapes BRCA1-dysregulated ovarian cancer morphological plasticity
P2860
Q26744538-3ACF09B7-4352-4FF8-9B40-5F4F14FB74DEQ27024580-CEE1C538-906F-432C-89DE-76232692D7C5Q27687444-A0198AF8-8435-4EA4-AC93-9723FC8E79A5Q33718563-3F2C3D56-C173-4314-A7B3-0487FC79521DQ33851283-276AF666-97D9-4EE3-B338-C01A2AD92E76Q34580297-4ADEA3EE-A6DA-4652-805C-CA6911533E61Q35782031-BCFDD7F5-760E-477C-AB7C-E1DA0AA0E6EBQ35890610-E8583036-7E4A-4DBE-BBFC-909767DC99A5Q35972468-92CA8A68-8555-41A7-B434-7217B3B31D83Q36191881-6F66A2D9-0D54-4F23-B335-252E7A931348Q36340825-A3CDBA99-FBE6-44CD-A18D-D890D56EC4CDQ36746278-48325B0B-0958-4F11-9787-09503BCCFD69Q37077413-394011E3-CA26-4BE5-99CA-0B640270F0DDQ37081973-62F851CE-60D9-4FA5-BABB-C8293D070CEBQ37105366-B3AA7A7B-2B36-4A27-848C-45AED1E94BA7Q37413162-1D7BECF7-6D6A-48C9-9F2E-8AF59B685D10Q37448685-8C5EE17A-6027-48CA-9B17-C5D35A88D279Q37581540-65D2FFE1-1560-4DAB-9645-B7E9BD583BB3Q37661404-1A3EE01D-E579-4568-B2C2-13F36DA6B9ECQ37736079-7467D83C-6506-48D0-8533-7EAAA0EBF87CQ38005176-06E73B29-4708-421F-9DD5-5B01481F829AQ38121746-0E025F79-6D60-4473-B8CF-7BECE2F1F07BQ38254055-AB737AC4-A08D-49EE-8924-64D05404FB7EQ38285397-81512411-4194-421D-8978-7E02C6AA1FFAQ38710871-EC29974F-A421-4C83-A784-88455618B86FQ39242218-401417AC-7C7A-406E-A3D8-C1EF9317EFD7Q39374390-567B8DA6-DD6A-4CD8-AA16-30E92EEB2DAFQ39431541-C5838902-6D0F-4008-8E98-D7ACF9E8892FQ42177420-424CBBFB-51EE-4820-8B30-AD000B6F8E3BQ45072735-BD771BB9-DEE1-42D0-B2F3-813000B35BF0Q47139274-523D94F5-BA15-47EF-A9B6-836672B319ABQ48159180-2F49E878-0C0B-4CD6-BED0-BD4A0BA5EFA8Q50465411-EF2253E0-0EC4-4734-A9DD-55362C9CAC4FQ52331518-A196CA97-0C51-4DFC-989D-CC6A0868767AQ52607627-E9396FE2-9423-4801-A3D7-C8B4F6DAF25EQ52699529-0FFF6DFB-8981-4360-BE36-31F55C57212CQ55119445-09781248-5857-4BD7-99FC-226EF3E65B1EQ55152503-5325289D-3861-4324-B9D6-F3802395A78CQ58698836-772F9031-744D-4237-8DE7-6E69CEE519F9
P2860
A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans
@ast
A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans
@en
A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans
@en-gb
A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans
@nl
type
label
A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans
@ast
A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans
@en
A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans
@en-gb
A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans
@nl
prefLabel
A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans
@ast
A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans
@en
A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans
@en-gb
A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans
@nl
P2093
P2860
P3181
P356
P1433
P1476
A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans
@en
P2093
Chikara Ohyama
Hisao Saitoh
Kanemitsu Yamaya
Kazuyuki Mori
Mihoko Sutoh
Minoru Fukuda
Nobuyoshi Hiraoka
Shigeru Tsuboi
Shingo Hatakeyama
Takahiro Yoneyama
P2860
P304
P3181
P356
10.1038/EMBOJ.2011.215
P407
P577
2011-08-03T00:00:00Z